Alphyn to Present Poster on Zabalafin Hydrogel Clinical Results at European Academy of Dermatology and Venereology Congress 2024

The poster, titled "Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin," is authored by Lynda Spelman, MD1, Stephen Shumack, MD2, Michael Benson, MD3, Bevin Bhoyrul, MD4, Jessie Lee, MD5, Ebrahim AK Abdulla, MD6, Neal Koller7, and Gary Pekoe, PhD7 The poster, titled "Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin," is authored byLynda Spelman, MD 1,Stephen Shumack, MD 2,Michael Benson, MD 3, Bevin Bhoyrul, MD...

The poster, titled "Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin," is authored by Lynda Spelman, MD¹, Stephen Shumack, MD², Michael Benson, MD³, Bevin Bhoyrul, MD⁴, Jessie Lee, MD⁵, Ebrahim AK Abdulla, MD⁶, Neal Koller⁷, and Gary Pekoe, PhD⁷

Zabalafin Hydrogel is a novel, first-in-class complex single-source botanical drug with multiple bioactive compounds that provide multiple mechanisms of action, including anti-pruritic, antibacterial, and anti-inflammatory activity. The topical is derived from the company's Zabalafin Platform.

ABOUT ALPHYN BIOLOGICS

Alphyn Biologics, Inc. is a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics^® for severe and prevalent skin diseases based on its Zabalafin Platform. Its lead product candidate, Zabalafin Hydrogel, is being developed as a topical treatment for atopic dermatitis (AD), the most common form of eczema.

Zabalafin Hydrogel has demonstrated efficacy in Phase 2a clinical trials, and the company believes it will be the first therapeutic for AD to directly treat AD's itch and directly treat bacteria that are increasingly thought to cause AD's inflammation and flares. It also directly treats infected AD skin and directly treats AD's inflammation. Clinical trial results of Zabalafin Hydrogel suggest it has the potential to be the first AD treatment that is worry-free for long-term, continuous use.

Alphyn's Zabalafin Platform has multiple bioactive compounds and, therefore, multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics that have potential safety, side effect, patient tolerability, efficacy, and regulatory marketing authorization advantages. Alphyn is based in Annapolis, Maryland, and Cincinnati, Ohio, and has wholly-owned subsidiaries in Australia and Austria. The company became operational in 2020 and has raised approximately $16 million.

Logo - https://mma.prnewswire.com/media/1899346/Alphyn_Biologics__LLC__Logo_Hi_Res_Transparent_Bckgrd_Logov1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/alphyn-to-present-poster-on-zabalafin-hydrogel-clinical-results-at-european-academy-of-dermatology-and-venereology-congress-2024-302231194.html